BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Linagliptin: Phase III data

In a double-blind Phase III trial in 245 patients with inadequately controlled Type II diabetes, once-daily 5 mg oral linagliptin as an add-on to sulfonylurea met the primary endpoint of significantly reducing HbA1c from baseline to week 18 vs. placebo (0.47% placebo-adjusted mean reduction, p<0.0001). Additionally, a significantly greater proportion of patients receiving linagliptin achieved a reduction in HbA1c to...

Read the full 276 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >